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ScienceDirectA great burden of disease is attributable to human rhinovirus
(HRV) infections which are the major cause of the common
cold, exacerbations of both asthma and chronic obstructive
pulmonary disease (COPD), and are associated with asthma
development. Despite this there is currently no vaccine for
HRV. The first vaccine studies showed some promise in terms
of serotype-specific protection against cold symptoms, but
antigenic heterogeneity amongst the >150 HRVs has been
regarded as a major barrier to effective vaccine development
and has resulted in little progress over 50 years. Here we review
those vaccine studies conducted to date, discuss the
difficulties posed by antigenic heterogeneity and describe
some recent advances in generating cross-reactive antibodies
and T cell responses using peptide immunogens.
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Introduction
HRVs are small, non-enveloped RNA viruses belonging
to the picornaviridae family. HRVs comprise 3 species, A–
C, and are commonly referred to by numbered serotype.
HRVs have an icosahedral capsid comprising 60 copies of
each of four proteins, VP1–VP4, of which VP1–3 are
surface exposed and represent the major targets for anti-
body responses.
HRV infections are suffered by everyone. During child-
hood this is at a rate of 5–12 infections per year [1] and
importantly, infections continue throughout life suggest-
ing that effective immunity is either not developed or not
maintained. Infections in otherwise healthy adults cause
symptoms of the common cold. They also however causewww.sciencedirect.com much more severe disease. Respiratory virus infections,
the majority of which are HRVs, have been associated
with 60–80% and 40–50% of exacerbations of asthma and
COPD, respectively [2,3]. Recent reports suggest that
HRV C infection in particular is associated with severe
respiratory illness in children [4] and a large scale birth
cohort study has found that infections in early life are
associated with development of asthma later in child-
hood [5]. Given that the only available therapies are non-
prescription cold remedies or standard corticosteroid and
bronchodilator therapy in asthma and COPD, which is
regarded as inadequate during exacerbations, the medi-
cal need for a vaccine is clear. We review those HRV
vaccine studies conducted to date, highlighting
advances made in the last 3 years and discuss the
challenges posed by antigenic heterogeneity amongst
HRVs.
Antibodies can protect against infection
It was established soon after their discovery, in the
early1960s, that higher HRV-specific serum neutralising
antibody levels were associated with protection against
infection with a particular HRV type [6–8]. It was also
shown that nasal HRV-binding immunoglobulin (Ig) A
level is additionally associated with protection from sec-
ondary infection and/or symptoms [9]. Examination of the
protective effect of antibody has recently been extended
in a new cotton rat model of infection where both passive
transfer of immune serum and maternal antibody transfer
were shown to be capable of reducing lung virus titres
upon subsequent challenge [10]. These human studies
pre-dated the discovery of the HRV C species, but serum
HRV C-binding IgG1 was recently measured in two
studies and shown to be of significantly lower titre than
A and B species, which the authors suggest may indicate a
less efficacious humoral immune response to these virus-
es [11,12]. To determine if this translates to less protec-
tion against disease C species challenge studies are now
needed. This is however dependent on advances in
culturing C species HRVs, such as the recent develop-
ment of a differentiated sinus epithelial cell system [13]
in order to create an effective inoculum, because those C
species viruses tested to date do not infect conventional
cell lines used for virus propagation [14].
Early vaccine studies showed efficacy
A small number of human vaccine studies were con-
ducted in the few decades following the initial character-
isation of HRVs and showed some efficacy. Mitchison
et al. showed that an intramuscular prime-boost strategyCurrent Opinion in Virology 2015, 11:83–88
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Table 1
Summary of human vaccine trials and of animal studies involving virus challenge. I.M.: intramuscular, I.N.: intranasal, S.C.: subcutaneous.
Immunogen Delivery route Challenge Main findings Citation
Human trials
Whole HRV2
(formalin inactivated)
I.M. Yes Homologous virus infection: Reduced proportion vaccinated
subjects with cold symptoms versus unvaccinated controls, but
similar proportion with nasal virus isolation.
[15]
Heterologous virus infection: No protection from symptoms or
reduction in virus recovery.
Whole HRV13
(formalin inactivated)
I.N. Yes Reduced proportion of subjects with upper respiratory tract
symptoms versus unvaccinated controls (homologous virus
challenge). No difference nasal virus recovery.
[16]
Whole HRV13
(formalin inactivated)
I.N. Yes Protection from symptoms, reduced nasal virus shedding and
reduced duration of virus shedding versus unvaccinated controls
(homologous virus challenge) at 5 months post-immunisation.
[17]
No rise in cross-serotype reactive nasal neutralising antibody.
Whole decavalent
(formalin inactivated)
I.M. No Limited and variable rises in neutralising antibody titres to vaccine
serotypes.
[27]
Few increases in heterologous virus antibody.
HRV2 (Live, heat killed
or formalin inactivated)
I.N., I.M. or oral No I.M. vaccination gives similar or higher antibody titres as I.N.
challenge.
[28]
Animal studies
HRV16 VP0 peptide S.C. (Mouse) Yes Enhanced lung T cell and serum neutralising antibody responses to
challenge with heterologous viruses.
[33]
Whole HRV16 or HRV1B
(live)
I.M. (Rat) Yes Reduced lung and nasal tissue virus load with homologous but not
heterologous virus infection.
[10]with formalin inactivated HRV led to a reduction in rate
of symptomatic colds from 47% in unvaccinated subjects
to just 3.5% following homologous virus challenge two
weeks later. Although only 3.5% of vaccinated subjects
had a symptomatic cold, nearly half had recoverable virus
in the nose or rises in neutralising antibody titre post-
infection, suggesting that immunisation reduced disease
but did not prevent subclinical infection [15]. Adminis-
tration of formalin inactivated HRV via the nasal route
demonstrated similar protection in another study, this
time reducing symptomatic cold rates from 85% to 33%
upon subsequent RV13 challenge [16]. This protection
afforded by intranasal inactivated HRV against common
cold symptoms lasted until at least 5 months after vacci-
nation [17]. Table 1 provides a summary of those vaccine
studies carried out to date.
Antibody cross-reactivity amongst HRVs
Infection-induced antibody and inactivated, unadju-
vanted, whole virus immunisation can therefore provide
protection against infection, at least in terms of symp-
toms. However, the principle reason why these initial
vaccine studies were not built upon is the considerable
antigenic diversity amongst HRVs. HRV A and B species
in fact number 100 immunologically distinct serotypes as
determined by serum cross-neutralisation tests [18,19].
The more recently discovered C species comprises a
further 50–60 viruses, albeit as defined by genetic anal-
yses only. Studies of HRV evolution further show that
intra-species and inter-species recombination is common
[20,21]. Additionally, sequencing of clinical isolates in
paediatric populations show that a large number ofCurrent Opinion in Virology 2015, 11:83–88 distinct genotypes circulate within a community at any
given time [22–24]. Developing a vaccine which induces
sufficiently broad immunity therefore represents a very
significant challenge.
This is not to say there is not some antibody cross-
reactivity between HRVs because this has been demon-
strated both for neutralising antibody in immunised ani-
mals [25,26] and more recently in serum from human
subjects, where both within-species and between species
cross-reactivity was demonstrated for naturally occurring
VP1-binding IgG1 [12]. However, in those studies which
have assessed a significant number of serotypes, cross-
reactivity was shown to be somewhat limited because for
example only 13 of 37 tested antisera from whole virus
immunised rabbits neutralised a single other virus sero-
type [26]. The cross-reactive virus binding and virus
neutralising antibody responses in humans are also some-
what variable between individuals [12,27,28]. In terms of
protection against virus infection, secondary infection
with a heterologous virus serotype could reduce the
frequency and severity of symptoms similarly to a homol-
ogous virus reinfection in one study [29], but intramus-
cular inactivated vaccine provided no protection against
cold symptoms or virus shedding following heterologous
virus challenge in another [15]. Intramuscular live RV
immunisation in a cotton rat model caused reduced virus
titres upon subsequent homologous, but not heterologous
HRV infection [10]. Limited neutralising antibody cross-
reactivity also required multiple adjuvanted immunisa-
tions plus infection in mice [30]. That high antigenic
diversity should be a barrier to vaccine design is perhapswww.sciencedirect.com
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Mean linear amino acid sequence conservation amongst A (black line) and B (grey line) species HRVs. Mean conservation level calculated at each
position as a sliding window of 30 amino acids. Adapted from [33]. Conserved N-terminus regions (grey line) and VP0 immunogen (red line).not surprising when one considers that those neutralising
epitopes described [31,32] map to VP1, VP2 and VP3
capsid protein regions that recent full length HRV ge-
nome analyses have found to be the most highly variable
(as indicated by the major troughs in Figure 1) [21,33].
Intriguingly, a recent study has added further complexity
to this issue, suggesting that a large proportion of HRV
binding antibodies in human serum may also be misdir-
ected towards a non-protective epitope on VP1 [34].
A polyvalent vaccine comprising multiple HRV types is
one possible way of overcoming the issue of antigenic
diversity. A previous attempt at this strategy with forma-
lin inactivated decavalent whole virus preparations how-
ever demonstrated rises in neutralising antibody titres to
40% of serotypes at best [27]. A huge number of virus
types would also likely need to be contained in such a
vaccine because, as noted above, it has been found that
large numbers of strains circulate simultaneously, with for
example over 100 genetically distinct strains having been
found in a small paediatric cohort in just a 2 year periodwww.sciencedirect.com [22]. It seems therefore that an effective HRV vaccine
based solely on induction of neutralising antibody would
be required to induce a broadly cross-reactive response
based on the identification of new and highly conserved
neutralising epitopes.
Induction of cross-reactive antibodies using
peptide immunogens
Two recent studies have successfully generated cross-
reactive neutralising antibodies using peptide immuno-
gens. Edlmayr [35] immunised rabbits with recombinant
VP1 based on the sequence of two different viruses and
showed that both antisera were capable of inducing cross-
reactive neutralising antibodies, neutralising up to half of
ten other HRV serotypes tested. This study follows a
similar study utilising shorter VP1 and VP3 peptides in
which purified antibody from immunised rabbits neutra-
lised 60% of 48 tested serotypes [36]. The relatively low
amino acid conservation within VP1 perhaps makes these
results somewhat surprising. The VP4 capsid protein in
contrast is highly conserved, but because it is located onCurrent Opinion in Virology 2015, 11:83–88
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represent a good vaccine target. Interestingly then, Kat-
pally et al. [37] have defined a region of the n-terminus of
VP4 that is transiently exposed during a process termed
‘capsid breathing’ and showed that anti-serum raised
against a short VP4 peptide representing this region of
HRV14 neutralised heterologous serotypes. Misgivings
have been expressed about the potential efficacy of this
strategy of immunisation with short peptides, such as
whether immunogens need to recreate the complex dis-
continuous epitopes likely found on an intact capsid to be
efficacious and regarding the modest titres of neutralising
antibody short linear peptide immunogens induce [38].
However, given that the minimum protective neutralising
antibody titre in man is essentially unknown, these stud-
ies provide some promising findings which need to be
further tested for their ability to protect against infection
and disease.
T cell vaccine strategies
An alternative strategy with perhaps greater potential to
induce heterologous responses is to specifically induce
HRV-specific T cells because of their potential to re-
spond to highly conserved proteins not exposed on the
capsid surface. Amino acid sequences are highly con-
served in some non-structural proteins of HRVs as in
some other viruses [25,26] and there is some evidence
that T cells can be cross-reactive for HRV serotypes, both
in man [39] and in mice [40]. For influenza, higher
frequencies of cross-reactive T cells recognising internal
protein epitopes before infection has been associated
with reduced virus shedding and symptom severity
upon subsequent infection, independently of antibody
[41,42].
Based on these findings we have employed a mouse HRV
infection model [43] to determine if immunisation with
conserved HRV proteins can enhance T cell responses to
heterologous virus infection. We identified regions of the
VP0 (VP4 + VP2 precursor) capsid protein and the virus
polymerase as being highly conserved amongst A and B
species HRVs (Figure 1). In recombinant HRV16 VP0
immunised mice, antibodies and T cells reactive to
multiple other serotypes were detectable systemically.
After subsequent infection, activated CD4+ and CD8+
T cell number in the airways was increased. Importantly,
enhanced T cell responses were measured when mice
were challenged with heterologous A species serotypes
and lung cell responses to shorter VP0 peptides showed
that immunisation induced T cells responsive to a B
species serotype different from both the immunogen
and the infecting virus. Whilst the immunogen did not
itself induce neutralising antibodies, immunisation en-
hanced neutralising antibody responses to heterologous
infecting virus, indicating that boosting of neutralising
antibody was dependent on B cell help elicited by cross-Current Opinion in Virology 2015, 11:83–88 reactive CD4+ T cells and thus that humoral responses to
any subsequent infection might be enhanced [33].
As with the other animal studies discussed, the mouse
model in which these studies were undertaken differs to
human infection in terms of the comparatively limited
and short-lived replication, the measurement of immune
responses in the lower rather than upper airways and
perhaps importantly, that animals had not experienced
the previous infections experienced by a human subject.
This work however provides a promising initial proof of
concept for a T cell inducing HRV vaccine which can now
be tested in human models of HRV challenge in healthy
subjects, of asthma exacerbation [44–47] and of COPD
exacerbation [48].
Conclusions
A handful of studies some 40–50 years ago remain the
only human vaccine trials to have been conducted for
HRVs despite their huge disease burden. This lack of
progress within the field can be largely attributed to the
issue of antigenic heterogeneity. There are however
studies now showing that antibodies with limited cross-
serotype reactivity can be generated by capsid peptide
immunisation and insights from influenza and now HRV
itself suggest that induction of cross-reactive memory
T cells could have efficacy in generating a broadly
cross-reactive vaccine. The availability of complete
HRV genome sequences will help in identification of
further conserved proteins which might be utilised as
immunogens. There is a need however for greater under-
standing of adaptive immune responses to HRV infec-
tion, especially to the poorly characterised C species
viruses, to identify the determinants of protection in
man. Understanding the role of T cells in disease must
be a priority given the few studies that exist. The
availability now of murine models of infection can only
help in speeding up this process. Finally, it is worth
noting that the problem of antigenic heterogeneity is
not exclusive to HRV vaccines and has been partially
overcome for influenza viruses by a large scale surveil-
lance programme which monitors circulating strains,
allowing selection of strains for the coming season’s
vaccine. Whilst it is already known that a large number
of HRV types circulate in a given population at any one
time, large scale and systematic monitoring would be
enormously beneficial in identifying how many differ-
ent HRV serotypes might need to be targeted, because
despite recent advances it seems unlikely that effective
protection against all human HRVs can be achieved
with a single immunogen.
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